Whitepaper: Measuring Certainty In The Specialty Pharmaceutical Supply Chain

By Alex Guite; Ruediger Lomb |

How Different Non-Excursion Rates Affect Performance

Like most industries, the pharmaceutical market has changed dramatically over the last few decades. The focus on highly profitable blockbuster drugs has been extended to include products targeted at smaller patient populations, including cell and gene therapies. Driving this is a determination from healthcare experts to find cures for diseases affecting millions across the world.

In this whitepaper, you'll learn:

  • How shifts in the industry are leading to more patient-centric healthcare practices
  • The difference between a 99.0% and 99.9% excursion rate
  • How today's pharmaceutical environment has become increasingly complex
                     Measuring Certainty

Access the whitepaper now to better identify the challenges in the Specialty Pharmaceutical Supply chain in relation to your organization.


About the Authors

Portrait of Alex Guite.

Alex Guite

Vice President, Services and Alliances
World Courier
View Bio
Portrait of Ruediger Lomb

Ruediger Lomb

Vice President, Global Quality and Compliance
AmerisourceBergen Global Commercialization Services & Animal Health
As the Vice President, Global Quality and Compliance for World Courier, as well as for Integrated Commercialization Solutions (ICS), Dr. Ruediger Lomb oversees the quality program for both entities, ensuring facility and process compliance with all current and future GxP standards such as relevant FDA guidelines, the most recent EU Good Distribution Practices Guidelines and other relevant quality standards. Dr. Lomb is a licensed pharmacist and holds a Ph.D. in pharmaceutical biochemistry.
View Bio